Clinical trials: Hyperphosphatemia Patients on Hemodialysis
Hyperphosphatemia
A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
This study is a randomized study designed as a 2x2 cross-over in two periods (Period 1 and Period 2) to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of EOS789 in patients with chronic kidney…
- Trial name
- NCT02965053
- Testing
- EOS789, Renvela
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Chugai Pharmaceutical
Hyperphosphatemia Patients on Hemodialysis
A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
An open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on hemodialysis
- Trial name
- NCT07548840
- Testing
- TS-172 20~60 mg/day
- Where
- Japan
- Volunteers
- 34 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Hyperphosphatemia, Chronic Kidney Disease
A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
This was a study to evaluate the efficacy and safety of HS219, chitosan-loaded chewing gum, when given three times a day for 3 weeks to the hemodialysis (HD) patients with hyperphosphatemia whose serum inorganic phosphorus was…
- Trial name
- NCT01039428
- Testing
- HS219
- Where
- 11 sites in Japan
- Volunteers
- 68 people
- Sponsor
- KDL Inc.
Hyperphosphatemia Patients on Hemodialysis
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
A phase 3, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis
- Trial name
- NCT07285291
- Testing
- TS-172 20~60 mg/day
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Hyperphosphatemia
Dose Finding Study to Treat High Phosphate Levels in the Blood.
Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks treatment period
- Trial name
- NCT02081534
- Testing
- AZD1722
- Where
- 41 sites in United States, Poland and 2 more
- Volunteers
- 162 people
- Sponsor
- Ardelyx
Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia
Low-Phosphate Diet and Fibroblast Growth Factor-23 Level
The aims of the study are to evaluate the effect of low-phosphate diet on FGF23 level and to determine the optimal amount of dietary phosphate restriction in hemodialysis patients.
- Conditions
- Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia, Dietary Intervention, Elevated Fibroblast Growth Factor-23
- Trial name
- NCT03367338
- Testing
- Low-phosphate diet
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- Wan-Chuan Tsai
Hyperphosphatemia, End Stage Renal Disease on Dialysis
Effectiveness of The Phosphate Mobile App on Serum Phosphorus in Adult Hemodialysis Patients With Hyperphosphatemia
This multi-centred randomized, open label-controlled trial consists of hemodialysis (HD) patients identified with hyperphosphatemia (>1.78mmol/L).
- Trial name
- NCT04789876
- Testing
- Phosphate mobile app, One-off dietary counselling with a phosphate booklet
- Where
- 3 sites in Malaysia
- Volunteers
- 74 people
- Sponsor
- Taylor's University
Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis
Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
The purpose of this survey is to evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.
- Trial name
- NCT01901107
- Testing
- Kiklin capsules
- Where
- 8 sites in Japan
- Volunteers
- 1,078 people
- Sponsor
- Astellas Pharma Inc
Hyperphosphatemia Patients on Hemodialysis
A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
A phase 2, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis
- Trial name
- NCT06745518
- Testing
- TS-172
- Where
- Japan
- Volunteers
- 62 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Renal Insufficiency, Chronic, Dialysis
Egg White for Phosphorus Control in Haemodialysis Patients
To evaluate the effect on phosphatemia in hemodialysis patients of replacing the meat or fish included in two meals a week with an amount of egg white containing the same quantity of proteins.
- Conditions
- Renal Insufficiency, Chronic, Dialysis, Hyperphosphatemia
- Trial name
- UAUDIPE (NCT03236701)
- Testing
- Egg White replacement
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Federico II University
Hemodialysis
Dietary Phosphorus Load and Postprandial Serum Phosphate in HD Patients
This study is to investigate the acute postprandial effect of a modified versus standard low phosphorus diet on serum phosphate, potassium and intact parathyroid levels in prevalent hemodialysis (HD) patients
- Trial name
- NCT04845724
- Testing
- Standard Diet, Modified Diet
- Volunteers
- 8 people
- Sponsor
- University College Cork
Chronic Kidney Disease, Renal Dialysis
Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease and hyperphosphatemia patients on hemodialysis.
- Conditions
- Chronic Kidney Disease, Renal Dialysis, Renal Insufficiency, Hyperphosphatemia
- Trial name
- NCT00892749
- Testing
- ASP1585
- Where
- 4 sites in Japan
- Volunteers
- 248 people
- Sponsor
- Astellas Pharma Inc
Hyperphosphatemia Patients on Hemodialysis
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
A phase 3, randomized, placebo-controlled, double-blind study of TS-172 in hyperphosphatemia
- Trial name
- NCT06745531
- Testing
- TS-172 20~60 mg/day
- Where
- Japan
- Volunteers
- 101 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Kidney Diseases, Renal Insufficiency
Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia
This is a randomized, dose-ranging, efficacy and tolerability study in chronic kidney disease patients with hyperphosphatemia on hemodialysis. Patient participation in the study is approximately 10 weeks in duration.
- Trial name
- NCT00358046
- Testing
- ILY101
- Where
- 18 sites in United States
- Volunteers
- 120 people
- Sponsor
- Ilypsa
Hyperphosphatemia, End-stage Renal Disease
Efficacy of Dietary Education and Education on Phosphate Binder Use in Hemodialysis Patients
Hyperphosphatemia is an independent risk factor for mortality among dialysis patients. And most phosphate in human is derived from the food.
- Trial name
- NCT02755961
- Testing
- Dietary education, Education on phosphate binder use
- Volunteers
- 70 people
- Sponsor
- Ajou University School of Medicine
Hyperphosphatemia
Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
To investigate the safety of repeated administration of KHK7791 for 52 weeks while switching from a phosphate-binding agent to KHK7791 in Hemodialysis patients with hyperphosphatemia.
- Trial name
- NCT04771780
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 213 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hyperphosphatemia
A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD
To evaluate the effect and safety of a switch from phosphate binders to KHK7791 to treat Hyperphosphatemia in patients on HD.
- Trial name
- NCT03831607
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 67 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hemodialysis, Hyperphosphatemia
Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study
The purpose of this study is to demonstrate decrease in cardiovascular mortality and morbidity in Japanese hemodialysis patients treated with Lanthanum carbonate compared with those with Calcium carbonate.
- Trial name
- LANDMARK (NCT01578200)
- Testing
- Lanthanum Carbonate, Calcium Carbonate
- Where
- Japan
- Volunteers
- 2,309 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
End-Stage Kidney Disease, Hyperphosphatemia
Explore the Effectors of The Transtheoretical Model on Nutritional Education in Patients on Hemodialysis
The purpose of this study is to assess the improvement degree of nutritional care program on the nutritional status and eating habits of hemodialysis patients
- Trial name
- NCT05897502
- Testing
- multimedia education
- Where
- Taiwan
- Volunteers
- 43 people
- Sponsor
- Liu, Liu-Yin
Hyperphosphatemia Patients on Hemodialysis
A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
A clinical study to evaluate the long-term safety and efficacy of TS-172 in hyperphosphatemia patients on hemodialysis.
- Trial name
- NCT07285304
- Testing
- TS-172
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.